Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;13:1129–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to Cancer therapy. Cancer Cell. 2015;27:450–61. https://doi.org/10.1016/j.ccell.2015.03.001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haanen JBAG, Van Thienen H, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015.
Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. https://doi.org/10.1186/s12916-015-0455-8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Costa RLB, Carneiro BA, Rademaker A, Agulnik M, Villaflor VM, Matsangou M, et al. Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2016;34(15_suppl):3064. https://doi.org/10.1200/JCO.2016.34.15_suppl.3064.
Article
Google Scholar
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013;369:122–33. https://doi.org/10.1056/NEJMoa1302369.
Article
CAS
PubMed
PubMed Central
Google Scholar
Viscoli C, Varnier O, Machetti M. Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification. Clin Infect Dis. 2005;40(Supplement_4):S240–5. https://doi.org/10.1086/427329.
Article
PubMed
Google Scholar
Sui J-D, Wang Y, Wan Y, Wu Y-Z. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. Drug Des Devel Ther. 2018;12:1645–57. https://doi.org/10.2147/DDDT.S167077.
Article
CAS
PubMed
PubMed Central
Google Scholar
Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, et al. Neutropenia in a patient treated with Ipilimumab (anti–CTLA-4 antibody). J Immunother. 2009;32:322–4. https://doi.org/10.1097/CJI.0b013e31819aa40b.
Article
PubMed
Google Scholar
Wei G, Nwakuche U, Cadavid G, Ajaz A, Seiter K, Liu D. Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Exp Hematol Oncol. 2012;1:3. https://doi.org/10.1186/2162-3619-1-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother. 2014;37:348–50. https://doi.org/10.1097/CJI.0000000000000041.
Article
PubMed
Google Scholar
Simeone E, Grimaldi AM, Esposito A, Curvietto M, Palla M, Paone M, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep. 2014;8:240. https://doi.org/10.1186/1752-1947-8-240.
Article
PubMed
PubMed Central
Google Scholar
Woźniak S, Mackiewicz-Wysocka M, Krokowicz Ł, Kwinta Ł, Mackiewicz J. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report. Oncol Res Treat. 2015;38:105–8. https://doi.org/10.1159/000377650.
Article
PubMed
Google Scholar
Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ipilimumab-Induced Neutropenia in Melanoma. J Investig Med High Impact Case Reports. 2016;4:232470961666183. https://doi.org/10.1177/2324709616661835.
Article
Google Scholar
Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer. 2016;99:123–6. https://doi.org/10.1016/j.lungcan.2016.06.026.
Article
PubMed
Google Scholar
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA, et al. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol. 2017;28:1672–3. https://doi.org/10.1093/annonc/mdx177.
Article
CAS
PubMed
Google Scholar
Wright Z, Brown A. High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. Blood Adv. 2017;1:1306–8. https://doi.org/10.1182/bloodadvances.2017008607.
Article
PubMed
PubMed Central
Google Scholar
Turgeman I, Wollner M, Hassoun G, Bonstein L, Bar-Sela G. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anti-Cancer Drugs. 2017;28:811–4. https://doi.org/10.1097/CAD.0000000000000520.
Article
CAS
PubMed
Google Scholar
Comito RR, Badu LA, Forcello N. Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract. 2019;25:221–5. https://doi.org/10.1177/1078155217726159.
Article
PubMed
Google Scholar
Meyers DE, Hill WF, Suo A, Jimenez-Zepeda V, Cheng T, Nixon NA. Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. Exp Hematol Oncol. 2018;7:6. https://doi.org/10.1186/s40164-018-0098-5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tokumo K, Masuda T, Miyama T, Miura S, Yamaguchi K, Sakamoto S, et al. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer. 2018;119:21–4. https://doi.org/10.1016/j.lungcan.2018.02.018.
Article
PubMed
Google Scholar
Meti N, Petrogiannis-Haliotis T, Esfahani K. Refractory neutropenia secondary to dual immune checkpoint inhibitors that required second-line immunosuppression. J Oncol Pract. 2018;14:514–6. https://doi.org/10.1200/JOP.18.00177.
Article
PubMed
Google Scholar
Ariane B, Maliha PG, Hudson M, Small D. A case of severe Pembrolizumab-induced neutropenia. Anti-Cancer Drugs. 2018;29:1. https://doi.org/10.1097/CAD.0000000000000661.
Article
CAS
Google Scholar
Tozuka T, Sugano T, Noro R, Takano N, Hisakane K, Takahashi S, et al. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxford Med Case Reports. 2018;2018. https://doi.org/10.1093/omcr/omy094.
Takahashi A, Kubo A, Mizuno S, Kasai K, Asai N, Yonezawa T, et al. Bicytopenia in primary lung melanoma treated with nivolumab. Intern Med. 2019.
Naqash AR, Appah E, Yang LV, Muzaffar M, Marie MA, McCallen JD, et al. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer. 2019.
Delanoy N, Michot J-M, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6:e48–57. https://doi.org/10.1016/S2352-3026(18)30175-3.
Article
PubMed
Google Scholar
Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25. https://doi.org/10.1016/j.ejca.2016.02.024.
Article
CAS
PubMed
Google Scholar
Bulbul A, Mustafa A, Chouial S, Rashad S. Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2017.
Sun Y, Lee SK, Oo TH, Rojas-Hernandez CM. Management of Immune-mediated Cytopenias in the era of Cancer immunotherapy. J Immunother. 2018;41:32–4. https://doi.org/10.1097/CJI.0000000000000194.
Article
CAS
PubMed
Google Scholar
Bryant AR, Perales MA, Tamari R, Peled JU, Giralt S. Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bone Marrow Transplant. 2018;53:1065–8. https://doi.org/10.1038/s41409-018-0142-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu C, Ding L, Zhu Y, Chen C. A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia. Ther Clin Risk Manag. 2017;13:1375–7. https://doi.org/10.2147/TCRM.S144681.
Article
PubMed
PubMed Central
Google Scholar
Finkel I, Sternschuss M, Wollner M, Shamai S, Peled N, Turgeman I, et al. Immune-related neutropenia following treatment with immune checkpoint inhibitors. J Immunother. 2019;00:1. https://doi.org/10.1097/CJI.0000000000000293.
Article
CAS
Google Scholar
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68. https://doi.org/10.1200/JCO.2017.77.6385.
Article
CAS
PubMed
Google Scholar
Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27:413–26.
Article
CAS
PubMed
Google Scholar
Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4:143–51. https://doi.org/10.1586/ehm.11.12.
Article
PubMed
Google Scholar
Gaertner J, Stamer UM, Remi C, Voltz R, Bausewein C, Sabatowski R, et al. Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017;31:26–34. https://doi.org/10.1177/0269216316655746.
Article
PubMed
Google Scholar
Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7–16. https://doi.org/10.1016/j.ejca.2018.07.129.
Article
CAS
PubMed
Google Scholar
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-Centre pharmacovigilance database analysis. Eur J Cancer. 2017.
Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793–801. https://doi.org/10.1016/S1074-7613(94)80021-9.
Article
CAS
PubMed
Google Scholar
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. https://doi.org/10.1038/nature13954.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–94. https://doi.org/10.1038/sj.leu.2404683.
Article
CAS
PubMed
Google Scholar
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. https://doi.org/10.1056/NEJMra1703481.
Article
CAS
PubMed
Google Scholar
Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol. 2015;11:243–57. https://doi.org/10.1517/17425255.2015.985649.
Article
CAS
PubMed
Google Scholar
Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, Thomae M, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin case–control surveillance study. Eur J Clin Pharmacol. 2015;71:219–27. https://doi.org/10.1007/s00228-014-1777-8.
Article
CAS
PubMed
Google Scholar
Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1 −/− mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 2015;61:1332–42. https://doi.org/10.1002/hep.27549.
Article
CAS
PubMed
Google Scholar
Sing C-W, Wong ICK, Cheung BMY, Chan JCY, Chu JKP, Cheung C-L. Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study. Pharmacoepidemiol Drug Saf. 2017;26:248–55. https://doi.org/10.1002/pds.4156.
Article
CAS
PubMed
Google Scholar
Young A, Quandt Z, Bluestone JA. The balancing act between Cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res. 2018;6:1445–52. https://doi.org/10.1158/2326-6066.CIR-18-0487.
Article
PubMed
PubMed Central
Google Scholar